mitoxantrone / Generic mfg. - LARVOL DELTA

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975) (ASH 2025) - P1 | "These patients will receive the common salvage regimen Idarubicin-fludarabine-cytarabine (IdaFLA) as the second cycle (Induction 2) in lieu of standard DA8 (Daunorubicin-Cytarabine) chemotherapy...In UPDATE AML, IR patients will receive VIA in place of MA (mitoxantrone-cytarabine) to eliminate exposure to the cardiotoxic agent mitoxantrone. HR patients will receive VIA as Intensification 1 prior to SCT, in place of the genotoxic agent etoposide and to provide venetoclax exposure prior to SCT...All newly diagnosed patients at TXCH >1 month to <30 years old with non-FLT3-ITD+ AML will be eligible for enrollment after completing standard Induction 1 chemotherapy consisting of combination of daunorubicin and cytarabine +/- gemtuzumab...Over 3 years, the study is anticipated to accrue 36-40 patients and generate important feasibility data for our treatment and molecular MRD innovations. Our results will inform future cooperative group trials with respect to..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Pediatrics • FLT3

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine (ASH 2025) - "Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after standard 7+3 induction (7 days of cytarabine plus 3 days of an anthracycline) is usually FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor [G-CSF], and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine)...Although the venetoclax–cytarabine (VEN-ARAC) or venetoclax–azacitidine (VEN-AZA) combination is approved as first-line therapy for unfit patients, it is generally not available in SUS... In this real-world study, VEN-based salvage therapy induced rapid and high CR rates after 7+3 or LDAC, with a favorable safety profile, and may serve as a less-toxic bridge to allo-HSCT."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Patterns of presentation, treatment, and survival in primary mediastinal B cell lymphoma: A colombian retrospective cohort (ASH 2025) - "R-CHOP protocol was the most common induction regimen (58.8%, n =10) followed by ABVD (23.5%, n=4), Bortezomib combined with Rituximab-Mitoxantrone (11.7%, n=2) and ICE (5,8%, n=1)...Likewise, there was a significant lack of access to Nivolumab and Brentuximab Vedotin, which has shown promising early efficacy in patients with R/R PMBCL as has been described in large clinical trials such as CheckMate 436 (Zinzani et al., 2019)... This small single center retrospective cohort study is one of the first to be conducted regarding PMBL in Latin America and to our knowledge first conducted in Colombia. Our findings regarding survival suggest efficient disease control, however with a high risk for late relapse beyond five years. In that sense, larger local real world studies are needed and it is crucial to emphasize on diagnosis and treatment strategies used in this region in order to optimize clinical outcomes in resource limited settings."

Retrospective data • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases • CD20 • MME • TNFRSF8

Efficacy of novel agents in the treatment of acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis (ASH 2025) - "Newer agents included for AML were Guadectiabine, Magrolimab, Alvocidib, Enasidenib, Flotetuzumab, Vadastuximab, Mitoxantrone, Pevonedistat, Entospletinib, Eprenetapopt, Belinostat, Onvansertib, Panobinostat, Cediranib Maleate, Nilotinib, Emavusertib, and anti-CD45 antibody (DOTA-BC8). The newer agents investigated for MDS included Rigosertib, Imetelstat, Pembrolizumab, Enasidenib, Sabatolimab, Ivosidenib, Elitercept, Pevonedistat, Emavusertib, Atezolizumab, and Olutasidenib...All patients were treated concomitantly with either azacitidine (77%) or decitabine (23%)... This meta-analysis and systematic review demonstrate promising efficacy for novel agents in AML and MDS patients. There is a need for prospective trials with larger patient populations to investigate these agents further."

Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neutropenia • TP53

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study (ASH 2025) - P2 | "Venetoclax, a BCL-2 inhibitor, has shown promisein combination with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine, achievinga reinduction rate of approximately 40%...Eligible patients were randomized 1:1 to receive either CAV (cladribine 5 mg/m2/day, cytarabine20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21) or MEC (mitoxantrone8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5)...Our findings demonstrate that the CAV regimen represents an effective and well-tolerated salvagetherapy for R/R AML, particularly in venetoclax-naïve patients who achieved significantly superiorresponse rates. These promising results warrant further validation in larger prospective studies toconfirm the regimen's efficacy."

Clinical • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock

Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples (ASH 2025) - "Cells were seeded into 384-well plates and exposed to variousconcentrations of five drug pairs—two venetoclax (VEN)-based (VEN+decitabine, or VEN+azacitidine) andthree cytarabine (CYT)-based (CYT+daunorubicin, CYT+mitoxantrone, or CYT+idarubicin). In three patients, synergy was comparably high for both VEN- and CYT-basedpairs, whereas another three exhibited uniformly low synergy across all combinations. These findingsunderscore the potential of ex vivo synergy profiling to stratify AML patients for individualizedcombination therapy selection."

Heterogeneity • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD20

Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA (ASH 2025) - "Therefore, to better distinguish outcomes in fit patients after Ven/HMA, and alsoto report outcomes after a cladribine based salvage regimen, which represents a common salvageapproach in R/R AML, we report the outcomes of this approach in pts treated at our institution.METHODSWe performed a retrospective study of pts with AML receiving either CLAG-M (cladribine 5mg/m2 D1-5,cytarabine 2G/m2 D1-5, G-CSF D1-5, mitoxantrone 10mg/m2 D1-3) or Cladribine-LDAC (cladribine5mg/m2 D1-5 cytarabine 40mg SQ D1-10) after receiving treatment with Ven/HMA. 7 pts were successfully bridged to allogeneic HCT,median OS among these pts was 8.8 mo.CONCLUSIONAmong fit AML pts receiving ven/HMA in a prior line, salvage chemotherapy with CLAG-M is reasonable,particularly if a pt requires bridging therapy for possible allogeneic HCT. Outcomes with CLAG-M salvageoverall remains suboptimal, necessitating the development of novel salvage therapies in patientspreviously exposed to ven/HMA."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • TP53

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia (ASH 2025) - "All received the XAB regimen: selinexor (35 mg/m² twice weekly), azacitidine (75mg/m²/day days 1–5), and venetoclax (100mg day 1, 200mg day 2, and 400 mg daily days 3- 21)...These early responders continued XAB for a second week, with all 8 (100%) maintainingCR/CRi; transplant-eligible patients will proceed to two cycles of consolidation (X + Ara-C +idarubicin/mitoxantrone) followed by allo-HCST The remaining 13 patients (61.9%) with PR/NR at week 1received XAB + A50 during week 2... Bone marrow blast reduction kinetics (Types A-D) robustly predict therapeutic efficacy of theXAB regimen across AML disease states. In R/R AML, Type A kinetics identify patients benefiting fromcontinued XAB (100% CR/CRi). In ND AML, this regimen achieves 100% CR/CRi in rapid responders."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy (ASH 2025) - P1/2 | "This post hoc analysis evaluated the efficacy andsafety of olutasidenib monotherapy in a subset of patients (n=105) from the phase 2 pivotal cohort whohad received prior intensive chemotherapy (IC; e.g., high-dose cytarabine with daunorubicin,mitoxantrone with etoposide and cytarabine, or transplant conditioning regimens). The pivotal cohort of the global, multicenter, registrational, open-label phase 2 trial assessedolutasidenib 150 mg BID in adults with R/R AML harboring mIDH1. Among this cohort of patients with R/R mIDH1 AML who had received prior IC, treatmentwith olutasidenib monotherapy produced clinically meaningful response rates that closely align withthose observed in the overall population, with durable responses and acceptable tolerability. Thesefindings support the utility of olutasidenib in patients previously treated with intensive chemotherapy."

Clinical • Monotherapy • Acute Myelogenous Leukemia • Constipation • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Neutropenia • IDH1

FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML. (ASH 2025) - "Background FLAG (G-CSF, Fludarabine, Cytarabine) combined with either Idarubicin (Ida) or Mitoxantrone (Mitox) werereported to be effective and well tolerated regimens in newly diagnosed (ND) or relapsed/refractory (R/R)Acute Myeloblastic Leukemia (AML)...FLAG-Mitox +Ven regimen combined G-CSF (5μg/kg/d) on d1-7.Fludarabine (30mg/m2/d IV) and Cytarabine (1.5g/m2/d IV) on d2-5, Mitox (12mg/m2/d IV) d2,4 and Ven(100mg PO daily) given concomitantly with voriconazole d2-8...Among the 50 R/R pts, first induction therapy consisted of 7+3regimen in 32 pts (64%), FLAG-Ida in 15 pts (30%) and 5-Azacytidine+Ven in 3 pts (6%)...High survival outcomes were demonstrated across ELN 2022 riskgroups in ND AML pts. This regimen is also an effective bridge to AHSCT when feasible."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation • FLT3

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study (ASH 2025) - "Introduction: The prognosis of newly diagnosed FLT3-mutated adult acute myeloid leukemia (AML) hasrecently improved by the combination of standard chemotherapy with FLT3 inhibitors, midostaurin orquizartinib...The first cycle was the remission induction treatment that comprised theadministration of MEC (mitoxantrone 8 mg/m2 intravenous infusion, days 1-3; etoposide 100 mg/m2intravenous infusion, days 1-5; cytarabine 100 mg/m2 continuous intravenous infusion, days 1-7) followedby gilteritinib (120 mg/day orally, day 8-28)... Sequential administration of MEC chemotherapy followed by gilteritinib demonstrated highrates of CR and CRc and manageable toxicity in patients with R/R FLT3-mutated AML. The hightherapeutic efficacy of this combination was supported by the high CR rate achieved prior to HSCT.Moreover, the treatment was well tolerated, with no early deaths observed."

Clinical • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia • FLT3 • NPM1

Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival (ASH 2025) - "Drug responses were highly variable across patients,with dasatinib, venetoclax, gilteritinib, and mitoxantrone showing the greatest inter-patient variability.Genomic stratification revealed established associations: TP53 mutations correlated with multi-agentresistance, while NPM1 and IDH1/2 mutations were associated with increased sensitivity to venetoclax-based combinations...Among ND patients treated withvenetoclax + hypomethylating agents (HMA), ex vivo sensitivity to venetoclax, azacitidine, and decitabineshowed strong correlation with overall survival (OS), with ROC-AUCs of 0.87, 0.67, and 0.87, respectively.Kaplan-Meier survival analysis based on DST-derived risk groups revealed significant differences:Venetoclax (hazard ratio, HR of 9.1, P10.0, P10, P<0.05)...Integration with genomicdata confirmed known drug–mutation relationships and revealed novel sensitivity patterns, includingIDH2–sorafenib and RUNX1–midostaurin. These findings support the incorporation of..."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ASXL1 • DNMT3A • FLT3 • IDH1 • IDH2 • NPM1 • RUNX1 • TP53

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial (ASH 2025) - "360 patients were randomised to FLA or HD AraC as course 3 and 4 in consolidation from Jan-2017 to Oct-2022; 180 to each arm.MethodsAt diagnosis 97% patients were allocated mitoxantrone and cytarabine (MA) with 79% receiving 1 or 3doses of GO in course 1 (Gibson, Blood; 144, Suppl 1, 2024)...SR patients received a second course of MA followed by two courses of either HD Ara C (3g/m2 bd ondays 1, 3, 5) or FLA (Fludarabine 30 mg/m2 and cytarabine 2g/m2 on days 1-5) based on randomisation.Randomisation was stratified by age; diagnosis (AML, MDS, and IMS); disease type (de novo, secondary); number of gemtuzumab ozogamicin (GO) doses...The median time from the start of course 3 to course 4 was 38 days for HD AraCand 41 for FLA.ConclusionFLA is not superior to HD AraC as consolidation therapy in children with SR AML. Patients with IRgenetics, particularly those with a non-high risk KMT2A rearrangement had a worse outcome with FLA.High Dose AraC should remain standard of care..."

Clinical • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Sarcoma • Solid Tumor • KMT2A

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831 (ASH 2025) - "AAML1831also decreased anthracycline exposure for LR1 patients by replacing mitoxantrone/cytarabine (MA) inCycle 4 with high-dose cytarabine/asparaginase (Capizzi). Comparison of data from the most recent COG AML phase 3 studies demonstrates that a subgroup ofpediatric AML patients (LR2) had superior outcomes with 5 chemotherapy cycles when compared to 4cycles. The lowest-risk patients with favorable genetics and good disease response (LR1) had nosignificant difference in RR or DFS with 4 chemotherapy cycles on AAML1831 compared to 5 cycles onAAML0531. Furthermore, this study demonstrates that in LR1 patients, substantial therapy reduction,including a 60% decrease in anthracycline exposure, can be achieved with outstanding survival."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Pediatrics • FLT3

Cost-effectiveness of post-transplant gilteritinib maintenance in MRD-positive FLT3-ITD Acute Myeloid Leukemia: A microsimulation model based on the morpho trial (ASH 2025) - "Salvage therapies were taken from ADMIRAL trial (Perl et al) and includedFludarabine/Cytarabine/G-CSF/Idarubicin (FLAG-Ida), Mitoxantrone/Etoposide/Cytarabine (MEC) (MEC),FLT3 inhibitors (gilteritinib), donor lymphocyte infusion (DLI), and second HCT. We found that gilteritinib maintenance was not cost-effective in a population with post-HCTMRD-positive FLT3-ITD AML. There was a large discrepancy in nets costs and effectiveness, suggestingthat gilteritinib prices could be lowered to better reflect the incremental improvement in clinicaloutcomes."

Clinical • Cost effectiveness • HEOR • Minimal residual disease • Post-transplantation • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Transplantation • FLT3

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML. (ASH 2025) - "Since the most benefitwas seen with GO given on days 1, 4, and 7 (fractionated GO, GO3) in the context of 7+3, wesubsequently conducted a single-arm phase 2 clinical trial of cladribine, high-dose cytarabine (HiDAC), G-CSF, and mitoxantrone (CLAG-M) + GO3. Pts with favorable-risk AML and MDS/AML who received HiDAC-based inductionchemotherapy +GO3 had low early mortality, infrequent liver injury, high rates of CR, and excellentsurvival outcomes, confirming this therapeutic strategy is well-tolerated and highly effective for favorablerisk AML."

Acute Myelogenous Leukemia • Hepatology • Liver Failure • BCORL1 • CEBPA • FLT3 • NPM1 • PTPN11 • SRSF2

The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication (ASH 2025) - "There are only a limited number of agentsthat are FDA approved for treatment of MDS including BCL2 and IDH inhibitors, hypomethylating agents(HMAs), ESAs, luspatercept and imetelstat...For MDS patients, weidentified the most effective agents with the proportion of sensitive samples noted in parentheses:mitoxantrone (100%), olutasidenib (78%), venetoclax (67%), dinaciclib (67%), trametinib (67%), olaparib(56%), GSK3368715 (56%), pacritinib (44%), lenalidomide (44%), fludarabine (55%), tasquinimod (44%),veliparib (44%). For sAML patients, we identified lenalidomide, olutasidenib, GSK3368715 have high DSSsin all tested samples, while fludarabine, fedratinib, tasquinimod, trametinib, veliparib, mitoxantrone andolaparib have high DSSs in 75% of the AML samples...Cancer Research 2024), and our samples included SF3B1 and U2AF1 mutations.Summary This study of the transition of MDS to sAML highlights molecular changes and reveals new drugsensitivity with agents that could be..."

Biomarker • Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • CD34 • FLT3 • JAK2 • NRAS • PTPN11 • SF3B1 • U2AF1

Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways (ASH 2025) - "To assess HSC transplantation efficacy, mice were conditioned with 700 or1000 Rads of TBI, transplanted with 2 million CD45.1 bone marrow (BM) cells, and monitored for donorcell engraftment for 4 months. Quizartinib synergized with DNA damaging chemotherapeutic agents (cyclophosphamide,carboplatin, cisplatin, temozolomide, and mitoxantrone) to deplete HSPC populations. Quizartinib sensitizes HSPCs to DNA-damaging therapies via downregulation of DNA repairgenes and impaired resolution of DNA damage, resulting in enhanced HSPC depletion. This quizartinib-driven sensitization demonstrated improved engraftment after HSCT in murine models. These resultsprovide a rationale for incorporating quizartinib into reduced-intensity, myeloablative conditioningregimens to improve transplant outcomes while minimizing non-hematopoietic toxicity."

Bone Marrow Transplantation • Transplantation • BRCA1 • BRCA2 • CD34 • FLT3 • NBN • PTPRC • RAD51

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia (ASH 2025) - "The median number of prior lines of therapy before VEN initiation was 1(range, 1–5); 19 pts (54%) were treated with VEN-based therapy in 1st salvage while 16 pts (46%) weretreated in 2nd or later salvage.VEN was combined with cladribine (+/- additional agents) in 17 pts (49%), including 8 (23%) who alsoreceived ruxolitinib. Nine pts (26%) were treated with VEN and pentostatin (+/- alemtuzumab), 3 (9%) withFCM (fludarabine, cyclophosphamide, mitoxantrone), 2 (6%) with alemtuzumab alone, 2 (6%) withruxolitinib alone, and 1 (3%) each with bendamustine or as monotherapy... Pts with R/R T-PLL continue to face poor prognosis. VEN-based therapies demonstrateencouraging response rates in this refractory, proliferative, heavily pretreated population, with improvedsurvival observed among responders and those with longer duration of 1st remission. However, OSremains short, highlighting the need for prospective trials to optimize VEN-based treatment and postremission strategies in..."

Clinical • IO biomarker • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Prolymphocytic Leukemia • Thrombocytopenia • JAK1 • JAK3 • STAT5B

Targeting CPNE8 suppresses HOXA9-dependent AML progression and overcomes chemotherapy resistance (ASH 2025) - "CPNE8-high PBMCs showed significantly elevated IC50 values across a range of clinicallyrelevant chemotherapeutics, including idarubicin, homoharringtonine, fludarabine, azacitidine,venetoclax, aclarubicin, all-trans retinoic acid (ATRA), and mitoxantrone. Importantly, both Menin inhibition and CPNE8 knockdown prolonged survival in CPNE8-high AMLxenograft models, underscoring their therapeutic potential.ConclusionCPNE8 functions as a critical downstream effector of HOXA9, driving AML progression and therapyresistance through activation of Rap1 signaling, reprogramming of mitochondrial metabolism, andreshaping of the immune microenvironment. Blocking the HOXA9–CPNE8–Rap1 pathway, especially withMenin inhibitors, provides a rationale for stratified treatment strategies in CPNE8-high AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • HOXA9

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia (ASH 2025) - P1 | "MEC, consisting of mitoxantrone, etoposide (ETOP), and cytarabine, is anestablished regimen for the treatment of R/R AML. Overall, combining peposertib with MEC was feasible and did not significantly affect ETOP PK. Despite thehigh risk and heavily pretreated study population, including 78% with prior venetoclax, activity was seenon multiple dose levels, including A2 and A4, which were both expanded and remain RP2D candidatesafter expansion. Additional PK and PD analyses, follow-up, and evaluation of duration of remission,event-free survival, and overall survival, will aid in selecting the final RP2D and informing future studies."

Clinical • Combination therapy • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Mucositis • Septic Shock • CYP3A4

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis (ASH 2025) - "Statistical analysis included descriptive analysis, Kaplan-Meier modeling, andmultivariable analyses for event-free survival (EFS) and overall survival (OS), with the multivariableanalysis constructed using treatment-related mortality (TRM) score. In this cohort, 21 patients (30%) were treated with both a purine analog (17 with cladribine, 4fludarabine) and an NRTI (9 with entecavir, 6 emtricitabine/tenofovir, 4 lamivudine, 2 tenofovirmonotherapy), with 13 of these patients receiving the purine analog for induction therapy. Amongst the38 patients who did not have the drug-drug interaction, for induction therapy, 22 (58%) receivedcladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M), 10 (26%) received a hypomethylating agent, 5(13%) received cytarabine and an anthracycline (7+3), and 2 (5%) received fludarabine, cytarabine, G-CSF,and idarubicin (FLAG-IDA)... Among patients with high-grade myeloid disease and HIV+ or HBV+ infection, concomitanttherapy with purine..."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Myelodysplastic Syndrome • CD4

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms (ASH 2025) - P2 | "Retrospectivedata from the pre-venetoclax era have suggested intensive therapies may lead to better outcomes thannon-intensive therapies in such patients, but few prospective comparisons have been conducted and therelative merits of individual treatment regimens are largely unknown... In this objectively frail, comorbid AML population, CLAG-M led to numerically but notstatistically significantly higher remission rates and survival than CPX-351. A randomized comparison ofintensive vs. lower-intensity therapy in a similar patient population is planned."

Clinical • P2 data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • FLT3 • TP53

Treatment-associated healthcare utilization in older adults with AML: A retrospective single-center study (ASH 2025) - "We aim to evaluate HCUpatterns in OA treated for AML and compare HCU patterns between hypomethylating agent-basedtherapy (HMA) and induction chemotherapy (IC), which may improve clinical decision-making and patientexpectations as well as serve as a baseline for improvement. We conducted a retrospective, single-center analysis of AML patients aged 65 and older whoreceived AML-directed treatment at UMass Memorial Medical Center between 2016 and 2023, excludingthose treated only with hydroxyurea...TP53 aberrations were more frequent in the HMA group (28%) compared to the IC group (5%).For initial treatment, 35 patients (41%) received HMA and venetoclax (median duration 16 days; range 1-32), 30 patients (35%) received HMA monotherapy; 20 patients (24%) received induction chemotherapy(IC), the majority of which consisted of mitoxantrone and cytarabine with or without FLT3 inhibitor, and 6patients (7%) received HMA with a FLT3 inhibitor.The minority of the cohort (14%)..."

HEOR • Retrospective data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • FLT3 • NPM1 • TP53

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials (ASH 2025) - "Following CR achievement, patientsreceived either busulfan (3.2 mg/kg IV or equivalent for 4 days) and cyclophosphamide (60 mg/kg for 2days) (Bu/Cy) followed by auto-HCT, or CT consisting of mitoxantrone (10 mg/m²/day) and etoposide (100mg/m²/day) for 5 days, according to protocol. Adjustment for covariates yielded similar resultsbetween auto-HCT and CT for RFS (favorable MRD-negative patients: HR 0.76, 95%CI: 0.38-1.53, p=0.45; intermediate MRD-negative patients: HR 0.88, 95%CI: 0.45-1.73, p=0.71; respectively) and OS (favorableMRD-negative patients: HR 0.81, 95%CI: 0.35-1.87, p=0.62; intermediate MRD-negative patients: HR 0.67,95%CI: 0.29-1.55, p=0.35; respectively).ConclusionsTreatment with Bu/Cy followed by auto-HCT is associated with similar RFS and OS in favorable andintermediate risk AML patients compared to CT when MRD guided treatment is used. CT was associatedwith longer durations for hematologic recovery and hospitalization."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Mucositis • Neutropenia • Pneumonia • Respiratory Diseases • Stomatitis • Transplantation